Vanguard Global Advisers
MCRB icon

Vanguard Global Advisers’s Seres Therapeutics MCRB Stock Holding History

Vanguard Global Advisers’s Portfolio MCRB Stock Details MCRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$15.6K Hold
1,975
– – ﹤0.01% 3393
2026
Q1 		$17.5K Buy
+1,975
New +$23.1K ﹤0.01% 3354

Other funds holding MCRB

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Vontobel Holding
Vontobel Holding Zurich, Switzerland $31.4B AUM 31.97% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
LPC
Lion Point Capital New York $20.9M AUM 195.52% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Vanguard Global Advisers's MCRB Position: Q2 2026 in Review

Vanguard Global Advisers held its Seres Therapeutics (MCRB) position steady in Q2 2026 at 1,975 shares worth $15.6K. The position accounts for ﹤0.01% of the portfolio, ranked #3393.

Vanguard Global Advisers first reported a position in MCRB in Q1 2026 and has held it in 2 quarters since. The position peaked at $17.5K in Q1 2026. 35 funds tracked by Wall St. Rank hold MCRB as of Q2 2026.

  • Vanguard Global Advisers held 1,975 shares of Seres Therapeutics worth $15.6K as of Q2 2026.
  • Vanguard Global Advisers left its Seres Therapeutics share count unchanged in Q2 2026.
  • Seres Therapeutics made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #3393 holding.
  • Vanguard Global Advisers first reported a position in Seres Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Global Advisers's Seres Therapeutics position peaked at $17.5K in Q1 2026.
  • 35 funds tracked by Wall St. Rank held Seres Therapeutics as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.